Breast cancer screening

Saudi Medical Journal

Volumn 25, Issue 8, 2004, Pages 991-997

  Altaf, Fadwa J ^a  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

[No Author keywords available]

Indexed keywords

ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BREAST CANCER; BREAST CARCINOMA; BREAST PAPILLOMA; CANCER INFILTRATION; CANCER SCREENING; CARCINOMA IN SITU; CELL PROLIFERATION; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EPITHELIUM HYPERPLASIA; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; LYMPH NODE DISSECTION; MAMMOGRAPHY; MASTECTOMY; MEDULLARY CARCINOMA; MUCINOUS CARCINOMA; PALPATION; RETROSPECTIVE STUDY; REVIEW; SAUDI ARABIA; SENSITIVITY AND SPECIFICITY;

ADULT; AGE DISTRIBUTION; AGED; BIOPSY, NEEDLE; BREAST NEOPLASMS; DEVELOPING COUNTRIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MASS SCREENING; MASTECTOMY; MIDDLE AGED; PREVALENCE; PROGRAM DEVELOPMENT; PROGRAM EVALUATION; RISK ASSESSMENT; SAUDI ARABIA; SURVIVAL ANALYSIS;

EID: 4544281015     PISSN: 03795284     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Shapiro S, Venet W, Strax P, Roeser R. Method of tumor detection, follow-up, and analysis in the Health Insurance Plan study: A randomized trial with breast cancer screening. Natl Cancer Inst Monogr 1985; 67: 64-74.
2. Cancer Care Ontario - Interim Cancer Report, April 24, 1998.
3. National Cancer Registry, Kingdom of Saudi Arabia, Ministry of Health, Cancer incidence report 1988-1997, 20-21.
4. Shapiro S. Evidence on screening for breast cancer from a randomised trial. Cancer 1977; 39: 2772-2782.
5. Shapiro S, Venet W, Strax P, Vent L, Roser R. Ten to fourteen year effect of screening on breast cancer mortality. J Nat'l Cancer Inst 1982; 69: 349-355.
6. Verbeek ALM, Hendricks JHCL, Holland R. Reduction in Breast cancer mortality through mass screening with modern mammography (First results of the Nijmegen Project 1975-81). Lancet 1984; 1: 1222-1224.
7. Tabar L, Fagerberg CJ, Gad A, Holmberg LH, Grontoft O, Ljungquist U et al. Reduction in mortality from breast cancer after mass screening with mammography. Lancet 1985; i: 829-832.
8. Elston CW, Ellis IO. Pathology of breast screening. Histopathology 1990; 16: 109-118.
9. Forrest APM. Breast cancer Screening. Report to the health Ministers of England, Wales, Scotland and Northern Ireland. London (UK): HMSO; 1986.
10. Blanks RG, Moss SM, Wallis MG. Use of two view mammography compared with one view in the detection of small invasive cancers: further results from the National Health Service breast screening programme. J Med Screen 1997; 4: 98-101.
11. Pathology Reporting in Breast Cancer Screening. Royal College of Pathologists Working Group. J Clin Path 1991; 44: 710-725.
12. Schnitt SJ, Conolly JL. Processing and Evaluation of Breast Excision Specimens, a clinical oriented approach. Review Article Anatomic Pathology. AJCP 1992; 13: 125-137.
13. Oberman HA, A Modest Proposal. Am J Surg Pathol 1992 16: 69-70.
14. Schmidt-Ullrich R, Wazer DE, Tercilla O, Safaii H, Marchant DJ, Smith J et al. Tumor margin assessment as a guide to optimal conservation surgery and irradiation in early stage breast carcinoma. Int J Radiat Oncol Biol Phys 1989; 17: 733-738.
15. Fisher ER, Sass R, Fisher B, Gregorio R, Brown R. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol 6). II. Relation of local breast recurrence to multicentricity. Cancer 1986; 57: 1717-1724.
16. Bartelink H, Borger JH, van Dongen JA, Peterse JL. The impact of tumor size and histology on local control after breast-conserving therapy. Radiother Oncol 1988; 11: 297-303.
17. Kurtz JM, Jacquemier J, Amalric R, Brandone H, Ayme Y, Hans D et al. Risk factors for breast recurrence in premenopausal and postmenopausal patients with ductal cancers treated by conservation therapy. Cancer 1990; 65: 1867-1878.
18. Veronesi U, Volterrani F, Luini A, Saccozzi R, Del Vecchio M, Zucali R et al. Quadrantectomy versus lumpectomy for small size breast cancer. Eur J Cancer 1990; 26: 671-673.
19. Solin LJ, Fowble BL, Schultz DJ, Goodman RL. The significance of the pathology margins of the tumor excision on the outcome of patients treated with definitive irradiation for early stage breast cancer. Int J Radiat Oncol Biol Phys 1991; 21: 279-287.
20. Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985; 312: 146-151.
21. Hutter RVP. Consensus meeting. "Is fibrocystic disease of the breast precancerous" Arch Pathol Lab Med 1986; 110: 146-151.
22. Page DL, Anderson TJ. Diagnostic histopathology of the breast. Churchill Livingstone; 1987. p. 51-61, 89-103, 104-119, 120-156, 146-151, 157-252.
23. Page DL, Steel CM, Dixon JM. Carcinoma in situ and patients at high risk of breast cancer. BMJ 1995; 310: 39-42.
24. American Cancer Society, Concensus conference on the classification of Ductal Carcinoma in situ. Hum Pathol 1997; 28: 1221-1225.
25. Rosen PP. Rosen's breast pathology. 2nd ed. Baltimore (MD): Lippincott William Wilkins; p. 303-356.
26. Summary report of the Working Group to review the national nacer Institute - American cancer Society of breast cancer detection demonstration projects, Section III Pathology review of Minimal Breast Cancer detection in BCDDP. J Nat'l Cancer Inst 1979; 62: 673-684.
27. Gallager HS. Pathologic types of breast cancer; their prognosis. Cancer 1984; 53: 623-629.
28. Anderson TJ, Alexander F, Chettyll U, Forrest AP, Kirk Patrick A, Muir B et al. Comparative pathology of prevalent and incident cancers detected by breast screening. Lancet 1986; 1: 519-522.
29. Page DL, Jensen RA, Simpson JF. Routinely available indicators of prognosis in breast cancer. Breast Cancer Res Treat 1998; 51: 195-208.
30. Dixon JM, Anderson TJ, Page DL, Lec D, Duffy SW, Stewart HJ. Infiltrating lobular carcinoma of the breast: An evaluation of the incidence and consequence of bilateral disease. Br J Surg 1983; 70: 513-516.
31. Marcus JN, Watson P, Page DL, Narod SA, Lenoir GM, Tonin P et al. Hereditary breast cancer: pathobiology, prognosis, and BRCA1 and BRCA2 gene linkage. Cancer 1996; 77: 697-709.
32. Esteban JM, Ahn C, Battifora H, Felder B. Predictive Value of estrogen receptors evaluated by quantitative immunohistochemical analysis in breast cancer. Am J Clin Pathol 1988; 19: 960-966.
33. Esteban JM, Ahn C, Battifora H, Felder B. Quantitative immunohistochemical assay for hormonal receptors: technical aspects and biological significance. J Cell Biochem 1994; 19: S138-145.
34. Connor AJM, Pinder SE, Elston CW, Bell JA, Wencyk P, Robertson JFR et al. Intratumoral heterogeneity of proliferation in invasive breast cancer evaluated with MIBI antibody. The Breast 1997; 6: 171-176.
35. Keshgegian AA, Cnaan A. Proliferation markers in breast carcinoma: Mitotic figure count, S phase fraction, proliferation cell nuclear antigen Ki-67 and MIB-1. Am J Clin Pathol 1995; 104: 42-49.
36. Kumar R, Sukumar S, Barbacid M. Activation of ras oncogenes preceding the onset of neoplasia. Science 1990; 248: 1101-1104.
37. Ohuchi N, Thor A, Page DL, Hand PH, Halter SA, Schlom J. Expression of the 21,000 molecular weight res protein in a spectrum of benign and malignant human mammary tissues. Cancer Res 1986; 46: 2511-2519.
38. Lodato RF, Maguire HS Jr, Greene MI, Weiner DB, LiVolsi VA. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990; 3: 449-454.
39. Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW et al. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Hum Pathol 1992; 23: 974-979.
40. Seth A, Palli D, Mariano JM, Metcalf R, Venanzoni MC, Bianchi S et al. p53 gene mutations in women with breast cancer and a previous history of benign breast disease. Eur J Cancer 1994; 30A: 808-812.
41. Mark DP, Gottfried K, Dennis JS. Use of HER2 for Predicting Response to Breast Cancer Therapy. Diseases of the Breast, Updates. No. 4; 1999. p. 1-10.
42. O'Mally FP, Unencak-Jones CL, Dupont WD. P53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994; 7: 67-72.
43. Moriya T, Sakamotok, Sasano H, Kawanaka M, Sonoo H, Manabe T et al. Immunohistochemistry analysis of Ki67, p53, p21 and p27 in benign and malignant apocrine lesions of the breast, its correlation to histologic findings in 43 cases. Mod Pathol 2000; 13: 838-841.